R&D News | pharmaphorum

News

US puts $25m behind Cellino's cell and tissue printing tech

Cellino Biotech has received funding from the US government to develop a scalable biomanufacturing platform for personalised regenerative medicines derived from patients' own stem cells.

News

Armed with $100m funding, F2G prepares to refile antifungal

UK biotech F2G has raised $100 million as it prepares to refile its olorofim candidate for invasive fungal infections, which was turned down last year by the FDA.

News

Moderna will cut $1.1bn off its annual R&D spend

Moderna is showcasing its R&D pipeline to investors today, but the headline news is a decision to cut its R&D spend by a massive $1.1 billion a year from 2027, reversing years of gr

News

Herpes simplex virus (HSV-2) capsid visualisation

GSK drops HSV jab, leaving rival mRNA shots in pole position

GSK has abandoned its clinical-stage vaccine for herpes simplex virus (HSV) after a disappointing phase 1/2 trial, ceding the ground to mRNA shots in development at Moderna and BioNTech.

News

Dupixent delivers in two skin disease trials

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications f

News

Meet MILTON, AZ's AI that can predict 1,000+ diseases

A machine-learning tool developed by AstraZeneca and trained on UK Biobank health record data could predict over 1,000 diseases, before diagnosis, according to a paper in Nature Genetics.

US puts $25m behind Cellino's cell and tissue printing tech

Armed with $100m funding, F2G prepares to refile antifungal

Moderna will cut $1.1bn off its annual R&D spend

GSK drops HSV jab, leaving rival mRNA shots in pole position

Dupixent delivers in two skin disease trials

Meet MILTON, AZ's AI that can predict 1,000+ diseases

BridgeBio gains on phase 3 dwarfism data

How to meet your physicians where they are online

News

Editor's Picks